Shay Shemesh Purchases 1,278 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCTGet Rating) insider Shay Shemesh bought 1,278 shares of the company’s stock in a transaction on Thursday, May 12th. The shares were acquired at an average price of $15.85 per share, with a total value of $20,256.30. Following the transaction, the insider now directly owns 1,240,893 shares in the company, valued at approximately $19,668,154.05. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

NVCT opened at $17.86 on Friday. Nuvectis Pharma, Inc. has a 12 month low of $3.08 and a 12 month high of $19.97. The company has a fifty day moving average price of $9.56.

An institutional investor recently bought a new position in Nuvectis Pharma stock. Ronit Capital LLP acquired a new stake in Nuvectis Pharma, Inc. (NASDAQ:NVCTGet Rating) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 550,000 shares of the company’s stock, valued at approximately $4,076,000. Nuvectis Pharma makes up approximately 5.1% of Ronit Capital LLP’s holdings, making the stock its 7th largest position. Ronit Capital LLP owned about 4.32% of Nuvectis Pharma as of its most recent SEC filing.

NVCT has been the subject of several recent research reports. Roth Capital reiterated a “buy” rating on shares of Nuvectis Pharma in a research report on Sunday, April 17th. HC Wainwright upped their target price on shares of Nuvectis Pharma from $14.00 to $21.00 in a research report on Tuesday.

Nuvectis Pharma Company Profile (Get Rating)

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases.

Featured Stories

Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with's FREE daily email newsletter.